Orionis Biosciences Inc.

Who: Pfizer/Triana Biomedicines What: Pfizer is partnering with Triana to discover novel molecular glue degraders for multiple targets in several disease areas. Why: Pfizer becomes the latest big

In Vivo's editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2023. Vote now in the polls below. T

Genentech is to collaborate with Orionis Biosciences to discover and develop new ‘molecular glue’ medicines, a field which is already attracting much big pharma investment. The biotech will receive

The once-shocking $100m-plus venture capital round is not such a shock anymore in the biopharmaceutical sector, since the number of mega-rounds has increased over the last few years as drug developmen